Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

The clinical profile of NMOSD in Australia and New Zealand.

Bukhari W, Clarke L, O'Gorman C, Khalilidehkordi E, Arnett S, Prain KM, Woodhall M, Silvestrini R, Bundell CS, Ramanathan S, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brownlee W, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Kilpatrick TJ, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonnell RAL, Mason DF, McCombe PA, Pereira J, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt J, Slee M, Taylor BV, Willoughby E, Wilson RJ, Brilot F, Vincent A, Waters P, Broadley SA.

J Neurol. 2020 Jan 31. doi: 10.1007/s00415-020-09716-4. [Epub ahead of print]

PMID:
32006158
2.

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.

Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, Yamout B, Hor JY, Karabudak R, Boz C, Ozakbas S, Olascoaga J, Simo M, Granella F, Patti F, McCombe P, Csepany T, Singhal B, Bergamaschi R, Fragoso Y, Al-Harbi T, Turkoglu R, Lechner-Scott J, Laureys G, Oreja-Guevara C, Pucci E, Sola P, Ferraro D, Altintas A, Soysal A, Vucic S, Grand'Maison F, Izquierdo G, Eichau S, Lugaresi A, Onofrj M, Trojano M, Marriott M, Butzkueven H, Kister I, Kalincik T.

Mult Scler Relat Disord. 2019 Nov 25;38:101868. doi: 10.1016/j.msard.2019.101868. [Epub ahead of print]

PMID:
31877445
3.

Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.

Zhou Y, Claflin SB, Stankovich J, van der Mei I, Simpson S Jr, Roxburgh RH, Kalincik T, Blizzard L, Lugaresi A, Alroughani R, Sajedi SA, Butzkueven H, Pucci E, Spitaleri D, Granella F, Cristiano E, Yamout B, Hughes S, Gouider R, Sánchez Menoyo JL, Olascoaga J, McGuigan C, Shaw C, Kermode AG, Kasa K, Al-Harbi T, Altintas A, Laureys G, Fragoso Y, Hardy TA, Csepany T, Sirbu CA, Decoo D, Sas A, Alvarez-Cermeño JC, Kotkata K, Millán-Pascual J, Taylor BV.

Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994. [Epub ahead of print]

PMID:
31668127
4.

Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.

Tur C, Kalincik T, Oh J, Sormani MP, Tintoré M, Butzkueven H, Montalban X.

Neurology. 2019 Oct 29;93(18):793-809. doi: 10.1212/WNL.0000000000008319. Epub 2019 Oct 7. Review.

PMID:
31591277
5.

Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle?

Wesselingh R, Butzkueven H, Buzzard K, Tarlinton D, O'Brien TJ, Monif M.

Front Immunol. 2019 Sep 10;10:2066. doi: 10.3389/fimmu.2019.02066. eCollection 2019. Review.

6.

Risk of secondary progressive multiple sclerosis: A longitudinal study.

Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T.

Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9.

PMID:
31397221
7.

Early imaging predictors of longer term multiple sclerosis risk and severity in acute optic neuritis.

Gajamange S, Stankovich J, Egan G, Kilpatrick T, Butzkueven H, Fielding J, van der Walt A, Kolbe S.

Mult Scler J Exp Transl Clin. 2019 Jul 23;5(3):2055217319863122. doi: 10.1177/2055217319863122. eCollection 2019 Jul-Sep.

8.

The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis.

Merlo D, Darby D, Kalincik T, Butzkueven H, van der Walt A.

Ther Adv Neurol Disord. 2019 Jul 12;12:1756286419859183. doi: 10.1177/1756286419859183. eCollection 2019.

9.

The MSBase registry: Informing clinical practice.

Kalincik T, Butzkueven H.

Mult Scler. 2019 Dec;25(14):1828-1834. doi: 10.1177/1352458519848965. Epub 2019 May 23.

PMID:
31120376
10.

Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis.

Hoepner R, Bagnoud M, Pistor M, Salmen A, Briner M, Synn H, Schrewe L, Guse K, Ahmadi F, Demir S, Laverick L, Gresle M, Worley P, Reichardt HM, Butzkueven H, Gold R, Metz I, Lühder F, Chan A.

Acta Neuropathol. 2019 Sep;138(3):443-456. doi: 10.1007/s00401-019-02018-8. Epub 2019 Apr 27.

11.

The role of vitamin D and P2X7R in multiple sclerosis.

Voo VTF, O'Brien T, Butzkueven H, Monif M.

J Neuroimmunol. 2019 May 15;330:159-169. doi: 10.1016/j.jneuroim.2019.03.004. Epub 2019 Mar 14. Review.

PMID:
30908981
12.

Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis.

Boonstra FM, Noffs G, Perera T, Jokubaitis VG, Vogel AP, Moffat BA, Butzkueven H, Evans A, van der Walt A, Kolbe SC.

Mult Scler. 2019 Mar 25:1352458519837706. doi: 10.1177/1352458519837706. [Epub ahead of print]

PMID:
30907236
13.

Prognosis in autoimmune encephalitis: Database.

Broadley J, Seneviratne U, Beech P, Buzzard K, Butzkueven H, O'Brien T, Monif M.

Data Brief. 2018 Nov 13;21:2694-2703. doi: 10.1016/j.dib.2018.11.020. eCollection 2018 Dec.

14.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

15.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.

PMID:
30636699
16.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group.

Mult Scler Relat Disord. 2019 Feb;28:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3.

PMID:
30623864
17.

Prognosticating autoimmune encephalitis: A systematic review.

Broadley J, Seneviratne U, Beech P, Buzzard K, Butzkueven H, O'Brien T, Monif M.

J Autoimmun. 2019 Jan;96:24-34. doi: 10.1016/j.jaut.2018.10.014. Epub 2018 Oct 26. Review.

PMID:
30595145
18.

Monitoring cognitive change in multiple sclerosis using a computerized cognitive battery.

De Meijer L, Merlo D, Skibina O, Grobbee EJ, Gale J, Haartsen J, Maruff P, Darby D, Butzkueven H, Van der Walt A.

Mult Scler J Exp Transl Clin. 2018 Dec 10;4(4):2055217318815513. doi: 10.1177/2055217318815513. eCollection 2018 Oct-Dec.

19.

Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure.

Geissbühler Y, Vile J, Koren G, Guennec M, Butzkueven H, Tilson H, MacDonald TM, Hellwig K.

Ther Adv Neurol Disord. 2018 Nov 3;11:1756286418804760. doi: 10.1177/1756286418804760. eCollection 2018.

20.

Obesity and brain volume loss in multiple sclerosis.

Marrie RA, Butzkueven H, Ascherio A.

Neurology. 2018 Dec 11;91(24):1079-1080. doi: 10.1212/WNL.0000000000006638. Epub 2018 Nov 14. No abstract available.

PMID:
30429279
21.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
22.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2019 Nov;25(13):1809-1818. doi: 10.1177/1352458518809326. Epub 2018 Nov 1.

23.

What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis.

Noffs G, Perera T, Kolbe SC, Shanahan CJ, Boonstra FMC, Evans A, Butzkueven H, van der Walt A, Vogel AP.

Autoimmun Rev. 2018 Dec;17(12):1202-1209. doi: 10.1016/j.autrev.2018.06.010. Epub 2018 Oct 11.

PMID:
30316992
24.

Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod: Incidence, Prevalence, and Impact on Disease Course.

Lim LL, Silva DG, Lo TC, Pimentel RS, Butzkueven H, Hall AJ.

Ophthalmology. 2019 Mar;126(3):438-444. doi: 10.1016/j.ophtha.2018.10.013. Epub 2018 Oct 10.

PMID:
30315901
25.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group.

Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.

PMID:
30298572
26.

Vitamin D for the treatment of multiple sclerosis: a meta-analysis.

McLaughlin L, Clarke L, Khalilidehkordi E, Butzkueven H, Taylor B, Broadley SA.

J Neurol. 2018 Dec;265(12):2893-2905. doi: 10.1007/s00415-018-9074-6. Epub 2018 Oct 3. Review.

PMID:
30284038
27.

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential.

Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, Ziemssen T, Ziemssen F, Frederiksen J, Xu L, Cadavid D; RENEW MF-VEP Investigators.

CNS Drugs. 2018 Dec;32(12):1159-1171. doi: 10.1007/s40263-018-0575-8.

28.

Validation of a precision tremor measurement system for multiple sclerosis.

Perera T, Lee WL, Yohanandan SAC, Nguyen AL, Cruse B, Boonstra FMC, Noffs G, Vogel AP, Kolbe SC, Butzkueven H, Evans A, van der Walt A.

J Neurosci Methods. 2019 Jan 1;311:377-384. doi: 10.1016/j.jneumeth.2018.09.022. Epub 2018 Sep 19.

PMID:
30243994
29.

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.

Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J.

Mult Scler. 2018 Oct;24(12):1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 20.

PMID:
30234431
30.

Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study.

Stein MS, Ward GJ, Butzkueven H, Kilpatrick TJ, Harrison LC.

Mol Med. 2018 May 30;24(1):27. doi: 10.1186/s10020-018-0028-3.

31.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
32.

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109.

33.

Novel Functional MRI Task for Studying the Neural Correlates of Upper Limb Tremor.

Boonstra FMC, Perera T, Noffs G, Marotta C, Vogel AP, Evans AH, Butzkueven H, Moffat BA, van der Walt A, Kolbe SC.

Front Neurol. 2018 Jul 2;9:513. doi: 10.3389/fneur.2018.00513. eCollection 2018.

34.

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators.

Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2.

35.

Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Menoyo JLS, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 May;22:166. doi: 10.1016/j.msard.2018.02.025. Epub 2018 Feb 24. No abstract available.

PMID:
29807821
36.

Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?

Jokubaitis VG, Zhou Y, Butzkueven H, Taylor BV.

Curr Treat Options Neurol. 2018 Apr 24;20(6):18. doi: 10.1007/s11940-018-0505-6. Review.

PMID:
29687310
37.

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Sánchez-Menoyo JL, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 Jan;19:105-108. doi: 10.1016/j.msard.2017.11.018. Epub 2017 Nov 22.

PMID:
29182993
38.

Tremor in multiple sclerosis is associated with cerebello-thalamic pathology.

Boonstra F, Florescu G, Evans A, Steward C, Mitchell P, Desmond P, Moffat B, Butzkueven H, Kolbe S, van der Walt A.

J Neural Transm (Vienna). 2017 Dec;124(12):1509-1514. doi: 10.1007/s00702-017-1798-4. Epub 2017 Nov 2.

39.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
40.

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group.

Mult Scler. 2018 Oct;24(12):1617-1626. doi: 10.1177/1352458517728812. Epub 2017 Aug 31. Erratum in: Mult Scler. 2017 Dec;23(14):NP1.

PMID:
28857680
41.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

42.

Multimodal characterization of gray matter alterations in neuromyelitis optica.

Liu Y, Jiang X, Butzkueven H, Duan Y, Huang J, Ren Z, Dong H, Shi FD, Barkhof F, Li K, Wang J.

Mult Scler. 2018 Sep;24(10):1308-1316. doi: 10.1177/1352458517721053. Epub 2017 Jul 25.

PMID:
28741987
43.

Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS.

Liu Y, Duan Y, Huang J, Ren Z, Liu Z, Dong H, Weiler F, Hahn HK, Shi FD, Butzkueven H, Barkhof F, Li K.

Eur Radiol. 2018 Jan;28(1):96-103. doi: 10.1007/s00330-017-4921-x. Epub 2017 Jun 30.

PMID:
28667482
44.

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.

Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Trojano M; Tysabri® Observational Program (TOP) Investigators.

Mult Scler. 2018 Jun;24(7):963-973. doi: 10.1177/1352458517709619. Epub 2017 May 30.

45.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

46.

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry.

Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

PMID:
28439957
47.

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.

Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T.

Autoimmun Rev. 2017 Jun;16(6):658-665. doi: 10.1016/j.autrev.2017.04.010. Epub 2017 Apr 17. Review.

48.

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M.

Mult Scler. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.

PMID:
28382837
49.

Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.

Nguyen AL, Gresle M, Marshall T, Butzkueven H, Field J.

Br J Pharmacol. 2017 Jul;174(13):1895-1907. doi: 10.1111/bph.13780. Epub 2017 Apr 26. Review.

50.

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S; RENEW Study Investigators.

Lancet Neurol. 2017 Mar;16(3):189-199. doi: 10.1016/S1474-4422(16)30377-5. Epub 2017 Feb 15.

PMID:
28229892

Supplemental Content

Loading ...
Support Center